Including 64 KEGG pathways in ASD, 26 in ID, 17 in EE and 34 in SCZ. |
KEGG accession | KEGG pathway name | Number of reference genes | Number of genes | Expected number | Ratio of entrichment | Raw P_Value | Adjusted P_Value | Genes related | Other disease |
---|---|---|---|---|---|---|---|---|---|
04810 | Regulation of actin cytoskeleton | 213 | 13 | 1.63 | 7.98 | 1.27e-08 | 1.23e-06 | SCZ | |
04510 | Focal adhesion | 200 | 12 | 1.53 | 7.84 | 5.59e-08 | 2.71e-06 | EE SCZ | |
04972 | Pancreatic secretion | 101 | 8 | 0.77 | 10.35 | 1.18e-06 | 3.82e-05 | EE | |
04971 | Gastric acid secretion | 74 | 7 | 0.57 | 12.36 | 1.67e-06 | 4.05e-05 | SCZ | |
04270 | Vascular smooth muscle contraction | 116 | 8 | 0.89 | 9.01 | 3.35e-06 | 6.50e-05 | SCZ | |
04970 | Salivary secretion | 89 | 7 | 0.68 | 10.28 | 5.80e-06 | 6.75e-05 | EE SCZ | |
05010 | Alzheimer's disease | 167 | 9 | 1.28 | 7.04 | 6.26e-06 | 6.75e-05 | ID | |
05414 | Dilated cardiomyopathy | 90 | 7 | 0.69 | 10.16 | 6.25e-06 | 6.75e-05 | EE SCZ | |
04512 | ECM-receptor interaction | 85 | 7 | 0.65 | 10.76 | 4.27e-06 | 6.75e-05 | SCZ | |
04020 | Calcium signaling pathway | 177 | 9 | 1.35 | 6.65 | 1.00e-05 | 9.70e-05 | EE SCZ | |
04912 | GnRH signaling pathway | 101 | 7 | 0.77 | 9.06 | 1.34e-05 | 0.0001 | ID SCZ | |
04070 | Phosphatidylinositol signaling system | 78 | 6 | 0.60 | 10.05 | 3.10e-05 | 0.0002 | - | |
05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 74 | 6 | 0.57 | 10.60 | 2.29e-05 | 0.0002 | ID SCZ | |
04540 | Gap junction | 90 | 6 | 0.69 | 8.71 | 6.96e-05 | 0.0005 | SCZ | |
04145 | Phagosome | 153 | 7 | 1.17 | 5.98 | 0.0002 | 0.0012 | - | |
04010 | MAPK signaling pathway | 268 | 9 | 2.05 | 4.39 | 0.0002 | 0.0012 | - | |
04360 | Axon guidance | 129 | 6 | 0.99 | 6.08 | 0.0005 | 0.0023 | - | |
04973 | Carbohydrate digestion and absorption | 44 | 4 | 0.34 | 11.88 | 0.0004 | 0.0023 | - | |
05222 | Small cell lung cancer | 85 | 5 | 0.65 | 7.69 | 0.0005 | 0.0023 | EE | |
05410 | Hypertrophic cardiomyopathy (HCM) | 83 | 5 | 0.64 | 7.87 | 0.0005 | 0.0023 | EE | |
04330 | Notch signaling pathway | 47 | 4 | 0.36 | 11.12 | 0.0005 | 0.0023 | - | |
04530 | Tight junction | 132 | 6 | 1.01 | 5.94 | 0.0006 | 0.0026 | ID SCZ | |
04310 | Wnt signaling pathway | 150 | 6 | 1.15 | 5.23 | 0.0011 | 0.0046 | - | |
05146 | Amoebiasis | 106 | 5 | 0.81 | 6.16 | 0.0014 | 0.0057 | EE SCZ | |
04114 | Oocyte meiosis | 112 | 5 | 0.86 | 5.83 | 0.0018 | 0.0070 | ID | |
04115 | p53 signaling pathway | 68 | 4 | 0.52 | 7.69 | 0.0019 | 0.0071 | - | |
04720 | Long-term potentiation | 70 | 4 | 0.54 | 7.47 | 0.0021 | 0.0075 | EE ID SCZ | |
04976 | Bile secretion | 71 | 4 | 0.54 | 7.36 | 0.0022 | 0.0076 | SCZ | |
05016 | Huntington's disease | 183 | 6 | 1.40 | 4.28 | 0.0030 | 0.0100 | ID | |
05322 | Systemic lupus erythematosus | 136 | 5 | 1.04 | 4.80 | 0.0041 | 0.0128 | - | |
04960 | Aldosterone-regulated sodium reabsorption | 42 | 3 | 0.32 | 9.33 | 0.0041 | 0.0128 | - | |
04914 | Progesterone-mediated oocyte maturation | 86 | 4 | 0.66 | 6.08 | 0.0044 | 0.0133 | SCZ | |
05215 | Prostate cancer | 89 | 4 | 0.68 | 5.87 | 0.0049 | 0.0144 | EE ID | |
04930 | Type II diabetes mellitus | 48 | 3 | 0.37 | 8.17 | 0.0060 | 0.0171 | EE | |
05213 | Endometrial cancer | 52 | 3 | 0.40 | 7.54 | 0.0074 | 0.0199 | - | |
04916 | Melanogenesis | 101 | 4 | 0.77 | 5.18 | 0.0077 | 0.0199 | ID | |
04150 | mTOR signaling pathway | 52 | 3 | 0.40 | 7.54 | 0.0074 | 0.0199 | - | |
05014 | Amyotrophic lateral sclerosis (ALS) | 53 | 3 | 0.41 | 7.40 | 0.0078 | 0.0199 | EE ID | |
05142 | Chagas disease (American trypanosomiasis) | 104 | 4 | 0.80 | 5.03 | 0.0085 | 0.0211 | - | |
05130 | Pathogenic Escherichia coli infection | 56 | 3 | 0.43 | 7.00 | 0.0091 | 0.0221 | ID | |
04660 | T cell receptor signaling pathway | 108 | 4 | 0.83 | 4.84 | 0.0097 | 0.0229 | - | |
05131 | Shigellosis | 61 | 3 | 0.47 | 6.43 | 0.0115 | 0.0266 | - | |
04670 | Leukocyte transendothelial migration | 116 | 4 | 0.89 | 4.51 | 0.0123 | 0.0277 | SCZ | |
05200 | Pathways in cancer | 326 | 7 | 2.49 | 2.81 | 0.0133 | 0.0293 | SCZ | |
05214 | Glioma | 65 | 3 | 0.50 | 6.03 | 0.0137 | 0.0295 | EE ID | |
04320 | Dorso-ventral axis formation | 24 | 2 | 0.18 | 10.89 | 0.0144 | 0.0297 | - | |
01100 | Metabolic pathways | 1130 | 16 | 8.65 | 1.85 | 0.0143 | 0.0297 | ID SCZ | |
00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 26 | 2 | 0.20 | 10.05 | 0.0168 | 0.0323 | - | |
03018 | RNA degradation | 71 | 3 | 0.54 | 5.52 | 0.0173 | 0.0323 | - | |
04722 | Neurotrophin signaling pathway | 127 | 4 | 0.97 | 4.12 | 0.0167 | 0.0323 | ID | |
04730 | Long-term depression | 70 | 3 | 0.54 | 5.60 | 0.0167 | 0.0323 | EE SCZ | |
05218 | Melanoma | 71 | 3 | 0.54 | 5.52 | 0.0173 | 0.0323 | - | |
05145 | Toxoplasmosis | 132 | 4 | 1.01 | 3.96 | 0.0189 | 0.0340 | SCZ | |
04080 | Neuroactive ligand-receptor interaction | 272 | 6 | 2.08 | 2.88 | 0.0189 | 0.0340 | EE ID | |
04514 | Cell adhesion molecules (CAMs) | 133 | 4 | 1.02 | 3.93 | 0.0194 | 0.0342 | SCZ | |
04370 | VEGF signaling pathway | 76 | 3 | 0.58 | 5.16 | 0.0207 | 0.0359 | - | |
04260 | Cardiac muscle contraction | 77 | 3 | 0.59 | 5.09 | 0.0214 | 0.0364 | EE | |
00020 | Citrate cycle (TCA cycle) | 30 | 2 | 0.23 | 8.71 | 0.0221 | 0.0370 | - | |
04664 | Fc epsilon RI signaling pathway | 79 | 3 | 0.60 | 4.96 | 0.0229 | 0.0376 | - | |
00640 | Propanoate metabolism | 32 | 2 | 0.24 | 8.17 | 0.0249 | 0.0403 | - | |
04350 | TGF-beta signaling pathway | 84 | 3 | 0.64 | 4.67 | 0.0268 | 0.0426 | ID | |
04012 | ErbB signaling pathway | 87 | 3 | 0.67 | 4.51 | 0.0294 | 0.0460 | - | |
00565 | Ether lipid metabolism | 36 | 2 | 0.28 | 7.26 | 0.0310 | 0.0477 | - |